Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China flag China · Delayed Price · Currency is CNY
44.41
+0.65 (1.49%)
Sep 14, 2026, 3:00 PM CST

Hangzhou Alltest Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
861.74899.45862.37752.263,3871,873
Other Revenue
5.95.94.222.441.470.86
867.64905.34866.58754.73,3891,873
Revenue Growth
-3.59%4.47%14.82%-77.73%80.88%64.98%
Cost of Revenue
445.38448.35392.82380.661,563843.87
Gross Profit
422.26456.99473.77374.041,8261,030
Selling, General & Admin
156.36159.06120.23135.87228.482.48
Research & Development
121.51109.3295.82121.17207.395.46
Other Operating Expenses
18.769.299.246.6627.559.87
Operating Expenses
299.8280.85233.17275.02471.08191.89
Operating Income
122.46176.14240.699.011,354837.67
Interest Expense
-0.28-0.28-0.42-1.46-2.17-0.67
Interest & Investment Income
19.7525.8345.6654.26744.86
Currency Exchange Gain (Loss)
-12.95-12.955.8515.8531.74-18.28
Other Non Operating Income (Expenses)
-31.81-1.830.81-1.330.73-3.95
EBT Excluding Unusual Items
97.17186.92292.51166.281,452859.63
Impairment of Goodwill
-----14.01-
Gain (Loss) on Sale of Investments
32.6140.6135.5532.67-15.2221.33
Gain (Loss) on Sale of Assets
0.660.61.22-0.660.52-0.08
Asset Writedown
-0.4---0.28-60.7-
Other Unusual Items
23.0523.0518.44-0.5719.1114.65
Pretax Income
153.09251.18347.71197.441,381895.53
Income Tax Expense
14.4831.144.817.16195.99129.84
Earnings From Continuing Operations
138.61220.07302.91180.281,185765.69
Minority Interest in Earnings
0.410.12-0.440.3-0.54-
Net Income
139.02220.19302.47180.581,185765.69
Net Income to Common
139.02220.19302.47180.581,185765.69
Net Income Growth
-55.24%-27.20%67.50%-84.76%54.75%12.73%
Shares Outstanding (Basic)
797979797975
Shares Outstanding (Diluted)
797979797975
Shares Change
0.51%0.03%-0.02%-0.07%5.96%25.16%
EPS (Basic)
1.752.783.822.2814.9510.24
EPS (Diluted)
1.752.783.822.2814.9510.24
EPS Growth
-55.47%-27.22%67.54%-84.75%46.05%-9.93%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
57.13-12.5108.87-508.731,090783.75
Free Cash Flow Per Share
0.72-0.161.38-6.4213.7610.48
Dividend Per Share
2.0002.0003.0001.5006.7572.703
Dividend Growth
33.33%-33.33%100.00%-77.80%150.00%99.99%
Gross Margin
48.67%50.48%54.67%49.56%53.87%54.96%
Operating Margin
14.11%19.46%27.76%13.12%39.97%44.71%
Profit Margin
16.02%24.32%34.90%23.93%34.97%40.87%
Free Cash Flow Margin
6.58%-1.38%12.56%-67.41%32.18%41.84%
EBITDA
169.2215.68266.44120.181,378846.45
EBITDA Margin
19.50%23.82%30.75%15.92%40.65%45.18%
D&A For EBITDA
46.7539.5325.8421.1723.118.78
EBIT
122.46176.14240.699.011,354837.67
EBIT Margin
14.11%19.46%27.76%13.12%39.97%44.71%
Effective Tax Rate
9.46%12.38%12.88%8.69%14.19%14.50%
Revenue as Reported
905.34905.34866.58754.73,3891,873